Publikation

Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly

Wissenschaftlicher Artikel/Review - 01.11.2017

Bereiche
PubMed
DOI
Kontakt

Zitation
Quarella M, Walser D, Brändle M, Fournier J, Bilz S. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. J Clin Endocrinol Metab 2017; 102:1451-1453.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
J Clin Endocrinol Metab 2017; 102
Veröffentlichungsdatum
01.11.2017
eISSN (Online)
1945-7197
Seiten
1451-1453
Kurzbeschreibung/Zielsetzung

Context
Diabetic ketoacidosis has been described as a rare complication of acromegaly and may be observed in 1% of affected patients. The well-described direct lipolytic effect of growth hormone results in increased availability of free fatty acids (FFAs) for hepatic ketogenesis and is an important pathogenic event. More recently, ketoacidosis has been identified as an important complication of sodium-glucose-transport-protein 2 inhibitors (SGLT2i). Increased pancreatic glucagon secretion, impaired renal ketone body clearance, and an increase in FFA concentrations secondary to decreased insulin concentrations are likely precipitating factors.

Case Description
We report a case of rapid-onset severe ketoacidosis within 2 days after adding empagliflozin to metformin, sitagliptin, and gliclazide in a presumably type 2 diabetic patient with unrecognized acromegaly and chronic hyperglycemia. Transsphenoidal resection of the growth-hormone secreting macroadenoma restored normal growth-hormone and insulinlike growth factor 1 concentrations and the diabetes was well controlled thereafter.

Conclusion
We hypothesize that SGLT2i, through their intrinsic effects on ketone body metabolism, may possibly precipitate ketoacidosis in patients with active acromegaly and diabetes mellitus.